The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization

banner

Agile Therapeutics Announces Allowance of Several Patents

26-Jul-2015 | Source : AG-IP News | Visits : 3920
PRINCETON, N.J. - Agile Therapeutics Inc., a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced in a press release that the US Patent and Trademark Office issued Notices of Allowance between July 21 and 23 for four patent applications with claims directed to novel transdermal contraceptive dosing regimens. 

The allowances of these patent applications provides the company with an additional proprietary platform for development of new products based on the Company's lead product candidate, Twirla® ethinyl estradiol and levonorgestrel transdermal system (AG200-15), currently in Phase 3 development. The four patent applications are published as US Publication Numbers 20110251163, 20110256210, 20110256211 and 20120021041. 

The allowed claims, which are available on the US Patent and Trademark Office website, are directed to various novel dosing regimens, each of which employs transdermal delivery of contraceptive doses of ethinyl estradiol and levonorgestrel during a "treatment interval" and transdermal delivery of low dose ethinyl estradiol and low dose levonorgestrel during a "withdrawal interval". 

The company expects these patents will be relevant to two of the products in the Agile pipeline, AG200-SP and AG200-ER, as well as other new potential regimens. "The allowance of these patent applications is an important milestone in building our women's health franchise beyond Twirla®. 

It validates our strategy for providing women additional contraceptive choices and demonstrates our commitment to develop unique follow-on products," said Al Altomari, Chief Executive Officer and President of Agile. About Agile Agile Therapeutics is a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products. Our product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. 
Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch currently in Phase 3 clinical development. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adherence and patient acceptability. 
 
share



Related Articles